T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant

Chapuis AG1,2,3, Egan DN2,3, Bar M2,3, Schmitt TM1,2, McAfee MS1,2, Paulson KG1,2,3, Voillet V4, Gottardo R4,5, Ragnarsson GB1,2,6, Bleakley M1,2,3, Yeung CC2,3, Muhlhauser P3, Nguyen HN1,7, Kropp LA1,2,8, Castelli L1,2,8, Wagener F1,2, Hunter D1,2, Lindberg M1,2,9, Cohen K4, Seese A4, McElrath MJ2,3,4, Duerkopp N1,2, Gooley TA2,5, Greenberg PD10,11,12,13. Author information 1 Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 2 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 3 University of Washington School of Medicine, Seattle, WA, USA. 4 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 5 Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 6 Landspítali Háskólasjúkrahús, Reykjavík, Iceland. 7 Alpine Biotech, Seattle, WA, USA. 8 Therapeutic Products Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 9 School of Informatics, University of Edinburgh, Edinburgh, UK. 10 Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. pgreen@u.washington.edu. 11 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. pgreen@u.washington.edu. 12 University of Washington School of Medicine, Seattle, WA, USA. pgreen@u.washington.edu. 13 Departments of Immunology and Medicine, University of Washington, Seattle, WA, USA. pgreen@u.washington.edu.